Fresita Proteins fixes ₹89.76 crore rights issue at ₹120

Fresita Proteins Ltd has fixed a rights issue of 74,79,917 equity shares at ₹120 each, raising up to ₹89.76 crore through an offer that opens on November 12, 2026 and closes on November 26, 2026. The fundraise gives eligible shareholders five rights shares for every six shares held on the October 30 record date.

What are the final terms of Fresita Proteins' rights issue?

Fresita Proteins has set the issue price at ₹120 per equity share, compared with a face value of ₹10 per share. The company plans to issue 74,79,917 fully paid equity shares, aggregating to approximately ₹89.76 crore, based on the stated issue size and price.

The entitlement ratio is 5:6. This means shareholders who held six fully paid shares on the record date of October 30, 2026 are entitled to apply for five additional equity shares. Shareholders may choose whether to apply for their entitlement, subject to the terms in the offer documents and the applicable application process.

The Board approved the final terms at its October 26, 2026 meeting. Fresita Proteins is listed on the BSE under scrip code 519242. The rights issue follows the board's earlier August 5 approval to raise an amount not exceeding ₹10,000 lakh, or ₹100 crore, through a rights issue.

When can shareholders apply for the Fresita Proteins rights issue?

The offer is scheduled to open on November 12, 2026 and close on November 26, 2026. October 29, 2026 was the last date to buy shares with eligibility for the rights issue, while October 30 was set as the record date for determining eligible shareholders.

Rights entitlements are scheduled to be credited on November 2, 2026. The disclosed timetable states that rights may be renounced until November 20, 2026. A separate schedule identifies November 27 as the deemed date of allotment, while the listing timetable indicates November 30, 2026 for listing of the new shares.

The Letter of Offer was filed with BSE on October 29, 2026. The company has stated that the process is being conducted under the Companies Act, 2013 and applicable Securities and Exchange Board of India regulations. MUFG Intime India Pvt. Ltd. has been named in the issue-related information provided.

Why is Fresita Proteins raising fresh equity capital?

Fresita Proteins has disclosed that a significant part of the proposed capital is earmarked for acquiring stakes in Fresita Food Private Limited and Urja Protein India Private Limited. The company has also expanded its business objects to include agriculture, horticulture and food processing.

These actions indicate that the company is positioning its operations towards a broader agri-food group structure. The disclosed materials do not provide a detailed allocation of the ₹89.76 crore among the proposed acquisitions, working capital, operating expenditure or other uses. Investors will need to refer to the offer documents for the stated objects of the issue and the related risk factors.

The company was formerly known as Sarda Proteins Limited. Its earlier rights issue approval had a ceiling of ₹100 crore, while the finalised offer size is lower at about ₹89.76 crore. The final terms therefore provide greater clarity on the actual number of shares, price and shareholder entitlement.

How does the rights issue affect Fresita Proteins shareholders?

The rights issue gives eligible shareholders a route to maintain their percentage ownership by subscribing to shares in their entitlement ratio. A shareholder who does not participate may see their relative ownership decline after the new shares are allotted, because the company's total outstanding equity share capital will increase.

The offer price is ₹120 per share, but the supplied disclosures do not establish a comparison with Fresita Proteins' market price. Therefore, no conclusion can be drawn from the available information on whether the offer is priced at a discount or premium to the prevailing BSE market quotation.

Shareholders should also note the timetable for renunciation. Eligible investors who do not intend to subscribe may consider the rights entitlement process within the specified deadline, subject to the facility, trading arrangements and instructions stated in the Letter of Offer. The company has disclosed that it is not a willful defaulter and has noted general risks associated with the offer.

What does this fundraise mean for Fresita Proteins' business strategy?

The rights issue links capital raising with Fresita Proteins' stated expansion into agriculture, horticulture and food processing. The proposed acquisitions of stakes in Fresita Food and Urja Protein India are the central disclosed strategic uses of the proceeds, making the fundraise relevant not only for the capital structure but also for the company's operating direction.

For investors, the key factual markers are the level of subscription, the allotment and listing of the rights shares, and disclosures on deployment of proceeds. The issue size of approximately ₹89.76 crore is material relative to the transaction described, but the supplied information does not include current financial performance, shareholding data or post-issue capital figures needed to quantify the eventual dilution precisely.

Conclusion

Fresita Proteins has finalised a ₹89.76 crore rights issue at ₹120 per share, with eligible shareholders receiving five rights shares for every six held on October 30, 2026. The offer formalises a previously approved equity fundraising plan and is connected with the company's proposed investments in Fresita Food Private Limited and Urja Protein India Private Limited.

The next disclosed dates are the issue opening on November 12, the renunciation deadline of November 20 and issue closing on November 26, 2026. Investors should watch the allotment and planned listing timetable, along with any further disclosures on the use of proceeds and the proposed acquisition stakes.